Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis

Fertility and Sterility

Volumn 87, Issue 1, 2007, Pages 163-171

  Laschke, Matthias W ^a   Elitzsch, Antje ^a   Scheuer, Claudia ^a   Vollmar, Brigitte ^b   Menger, Michael D ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

angiogenesis; cyclo oxygenase 2 inhibitor; dorsal skinfold chamber; Endometriosis; intravital fluorescence microscopy; Syrian golden hamster

Indexed keywords

CASPASE 3; CYCLINE; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYL SULFOXIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; VASCULOTROPIN;

ANALYTIC METHOD; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM GRAFT; FEMALE; FLUORESCENCE MICROSCOPY; HAMSTER; HISTOLOGY; MICROTHROMBUS; MITOSIS INHIBITION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CASPASE 3; CRICETINAE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOWN-REGULATION; ENDOMETRIUM; FEMALE; GRAFT SURVIVAL; MESOCRICETUS; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845751043     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.05.068     Document Type: Article

References (37)

1. Moghissi K.S. Medical treatment of endometriosis. Clin Obstet Gynecol 42 (1999) 620-632
2. Nothnick W.B., and D'Hooghe T.M. Medical management of endometriosis: novel targets and approaches towards the development of future treatment regimes. Gynecol Obstet Invest 55 (2003) 189-198
3. Sagsveen M., Farmer J.E., Prentice A., and Breeze A. Gonadotropin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 4 (2003) CD001297
4. Becker C.M., Bartley J., Mechsner S., and Ebert A.D. Angiogenesis and endometriosis. Zentralbl Gynakol 126 (2004) 252-258
5. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271 (1996) 33157-33160
6. Vane J.R., Mitchell J.A., Appleton I., Tomlinson A., Bishop-Bailey D., Croxtall J., et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 91 (1994) 2046-2050
7. Deguchi M., Ishiko O., Sumi T., Yoshida H., Yamamoto K., and Ogita S. Expression of angiogenic factors in extrapelvic endometriosis. Oncol Rep 8 (2001) 1317-1319
8. Ota H., Igarashi S., Sasaki M., and Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 16 (2001) 561-566
9. Chishima F., Hayakawa S., Sugita K., Kinukawa N., Aleemuzzaman S., Nemoto N., et al. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 48 (2002) 50-56
10. Cobellis L., Razzi S., De Simone S., Sartini A., Fava A., Danero S., et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 116 (2004) 100-102
11. Matsuzaki S., Canis M., Darcha C., Dallel R., Okamura K., and Mage G. Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril 82 (2004) 1609-1615
12. Dogan E., Saygili U., Posaci C., Tuna B., Caliskan S., Altunyurt S., et al. Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 82 Suppl 3 (2004) 1115-1120
13. Sawaoka H., Tsuji S., Tsujii M., Gunawan E.S., Sasaki Y., Kawano S., et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79 (1999) 1469-1477
14. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
15. Tuettenberg J., Grobholz R., Korn T., Wenz F., Erber R., and Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131 (2005) 31-40
16. Healy D.L., Rogers P.A., Hii L., and Wingfield M. Angiogenesis: a new theory for endometriosis. Hum Reprod Update 4 (1998) 736-740
17. Shifren J.L., Tseng J.F., Zaloudek C.J., Ryan I.P., Meng Y.G., Ferrara N., et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 81 (1996) 3112-3118
18. McLaren J., Prentice A., Charnock-Jones D.S., and Smith S.K. Vascular endothelial growth fac-tor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 11 (1996) 220-223
19. Williams C.S., Tsujii M., Reese J., Dey S.K., and DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105 (2000) 1589-1594
20. Buerkle M.A., Lehrer S., Sohn H.Y., Conzen P., Pohl U., and Krotz F. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 110 (2004) 2053-2059
21. Laschke M.W., Elitzsch A., Vollmar B., and Menger M.D. In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy. Fertil Steril 84 Suppl 2 (2005) 1199-1209
22. Menger M.D., Laschke M.W., and Vollmar B. Viewing the microcirculation through the window: some twenty years experience with the hamster dorsal skinfold chamber. Eur Surg Res 34 (2002) 83-91
23. Gross G.H. A technique for sustained synchronization of hamster estrous cycles by hormonal means. Horm Behav 9 (1977) 23-31
24. Laschke M.W., Menger M.D., and Vollmar B. Ovariectomy improves neovascularization and microcirculation of freely transplanted ovarian follicles. J Endocrinol 172 (2002) 535-544
25. Baker M., and Wayland H. On-line volume flow rate and velocity profile measurement for blood in microvessels. Microvasc Res 7 (1974) 131-143
26. Menger M.D., and Lehr H.A. Scope and perspectives of intravital microscopy-bridge over from in vitro to in vivo. Immunol Today 14 (1993) 519-522
27. Groothuis P.G., Nap A.W., Winterhager E., and Grummer R. Vascular development in endometriosis. Angiogenesis 8 (2005) 147-156
28. Taylor R.N., Lebovic D.I., and Mueller M.D. Angiogenic factors in endometriosis. Ann NY Acad Sci 955 (2002) 89-100
29. Vernon M.W., and Wilson E.A. Studies on the surgical induction of endometriosis in the rat. Fertil Steril 44 (1985) 684-694
30. Goteri G., Lucarini G., Filosa A., Pierantoni A., Montik N., Biagini G., et al. Immunohistochemical analysis of vascular endothelial growth factor cellular expression in ovarian endometriomata. Fertil Steril 81 (2004) 1528-1533
31. Laschke M.W., Elitzsch A., Vollmar B., Vajkoczy P., and Menger M.D. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 21 (2006) 262-268
32. Dormond O., Foletti A., Paroz C., and Ruegg C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7 (2001) 1041-1047
33. Yao M., Kargman S., Lam E.C., Kelly C.R., Zheng Y., Luk P., et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63 (2003) 586-592
34. Ueda M., Yamashita Y., Takehara M., Terai Y., Kumagai K., Ueki K., et al. Survivin gene expression in endometriosis. J Clin Endocrinol Metab 87 (2002) 3452-3459
35. Samaha H.S., Kelloff G.J., Steele V., Rao C.V., and Reddy B.S. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 57 (1997) 1301-1305
36. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
37. DuBois R.N., Shao J., Tsujii M., Sheng H., and Beauchamp R.D. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56 (1996) 733-737